Sermorelin Peptide

Sermorelin Peptide Therapy

Prices Starting at:

Oral $210

Injectable $270

1-month supply

What is Sermorelin?

Sermorelin is a synthetic peptide analogue of human growth hormone-releasing hormone (GHRH). It was developed by the German firm EMD Serono for the treatment of growth hormone deficiency (GHD) in both children and adults. The peptide’s primary function is to stimulate the manufacture and release of growth hormone (GH) in the human body.

Following clinical trials, sermorelin was initially approved by the U.S. Food and Drug Administration (FDA) in 1997 and sold under the trade name “Geref,” indicated for the treatment of growth hormone deficiency (GHD) in both children and adults. Its FDA approval was discontinued in 2008 for commercial reasons unrelated to its safety or efficacy .

Sermorelin was also used as a diagnostic agent for assessing whether a given patient’s pituitary gland was functioning properly and releasing adequate amounts of GH 1.

The peptide is now being researched for applications beyond the diagnosis and treatment of hormone deficiency, including for its role in sleep quality, heart health, and even as a novel brain tumor treatment.

What Does Sermorelin Do?

Sermorelin contains the first 29 amino acids of growth hormone-releasing hormone and is the shortest synthetic peptide to offer the full biological activity of endogenous GHRH.

As an analog of GHRH, sermorelin also binds to the growth hormone-releasing hormone receptor found in the anterior pituitary gland, signaling to the pituitary gland to produce and release more growth hormone in the body, by way of somatotropic cells.

Sermorelin’s mechanism is different from that of biosynthetic hGH, since injection of the latter can raise GH in the body to supraphysiological levels. On the other hand, the primary function of sermorelin is to mimic native GRF and stimulate GH secretion to the maximum natural level.